A Double Blind Clinical Trial of DCS for Food Anxiety
Information source: Washington University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Anorexia and Bulimia Nervosa
Intervention: Sertaline (Drug)
Phase: N/A
Status: Completed
Sponsored by: Washington University School of Medicine
Summary
This is a pilot study investigating if cycloserine (DCS; a learning enhancement medication)
augments exposure therapy for food anxiety in patients with anorexia and bulimia nervosa.
The investigators expect that (a) exposure therapy will reduce anxiety (b) anxiety will be
reduced more in the DCS relative to placebo condition (c) participants in the DCS condition
will have a greater increase in Body Mass Index.
Clinical Details
Official title: A Double Blind Clinical Trial of DCS for Food Anxiety for Patients With Anorexia and Bulimia Nervosa
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Anxiety
Secondary outcome: Body Mass Index
Eligibility
Minimum age: 14 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Diagnosed with Anorexia Nervosa, Bulimia Nervosa, Eating Disorder Not Otherwise
Specified
Exclusion Criteria:
- Pregnant or planning on becoming pregnant
- Psychotic or Manic
Locations and Contacts
Washington University, Saint Louis, Missouri 63130, United States
Additional Information
Starting date: February 2013
Last updated: December 9, 2014
|